FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012054395> ?p ?o ?g. }

• W2012054395 endingPage "816" @default.
• W2012054395 startingPage "814" @default.
• W2012054395 abstract "POINT-COUNTERPOINTInterleukin-6 does/does not have a beneficial role in insulin sensitivity and glucose homeostasisBente K. Pedersen, and Mark A. FebbraioBente K. Pedersen, and Mark A. FebbraioPublished Online:01 Feb 2007https://doi.org/10.1152/japplphysiol.01208.2006This is the final version - click for previous versionMoreSectionsPDF (51 KB)Download PDF ToolsExport citationAdd to favoritesGet permissionsTrack citations ShareShare onFacebookTwitterLinkedInEmailWeChat POINT: INTERLEUKIN-6 DOES HAVE A BENEFICIAL ROLE IN INSULIN SENSITIVITY AND GLUCOSE HOMEOSTASISGrowing evidence links Type 2 diabetes to a state of low-grade chronic inflammation, and it has been suggested that interleukin (IL)-6 promotes insulin resistance due to the observation that plasma IL-6 is often elevated in patients with metabolic disease. However, it is now well known that IL-6 is rapidly released into the circulation following exercise (8) and, from a simplistic physiological point of view, it seems paradoxical that working muscle would release a factor that inhibits insulin signaling when insulin action is enhanced in the immediate postexercise period (30). The idea of IL-6 being a bad guy with regard to metabolic actions is primarily based on 1) correlational relationships in cohort studies; 2) animal studies, neglecting that mouse and human IL-6 exhibit only ∼42% sequence identity, and 3) in vitro cell culture studies of supraphysiological concentrations of IL-6. In this review, we challenge the generally held view that IL-6 is a bad guy based on recent carefully conducted experiments in both in vitro and, importantly, humans in vivo.The in vivo effect of IL-6 on glucose and lipid metabolism.Although IL-6 appears to play a role in endogenous glucose production (EGP) during exercise in humans, its action on the liver is dependent on a yet unidentified muscle contraction-induced factor (7). In healthy humans in the basal condition, acute rhIL-6 administration at physiological concentrations does not impair whole body glucose disposal, net leg glucose uptake, nor does it increase endogenous glucose production (14, 17, 23). In patients with Type 2 diabetes, rhIL-6 decreases circulating insulin, suggesting an insulin-sensitizing effect of IL-6 (17). To test this hypothesis, we recently demonstrated that IL-6 increased glucose infusion rate and glucose oxidation without affecting the suppression of endogenous glucose production during a hyperinsulinemic euglycemic clamp in healthy humans (4). These data are in contrast with observations reported in mice (11). The finding of an insulin-sensitizing effect of IL-6 at conditions where EGP was completely suppressed underlines that in humans, the main effects of IL-6 with regard to glucose metabolism are likely to be in peripheral tissues (muscle, adipose), whereas IL-6 does not influence glucose output from the liver.Infusion of rhIL-6 into healthy humans to obtain physiological concentrations of IL-6 increased lipolysis in the absence of hypertriacylglyceridemia or changes in catecholamines, glucagon, insulin, or any adverse effects in healthy individuals (14, 17, 25) and in patients with Type 2 diabetes (17). These findings, together with cell culture experiments demonstrating that IL-6 alone markedly increases both lipolysis and fat oxidation, identify IL-6 as a novel lipolytic factor (17). Interestingly, Axokine, a human variant of the IL-6 family cytokine member ciliary neurotrophic factor (CNTF), which acts via a common receptor with IL-6 (the IL-6R/LIFR/ CNTFR/gp130 receptor complex), induces marked weight loss in obese patients (6). Moreover, blocking IL-6 in clinical trials with patients with rheumatoid arthritis leads to enhanced cholesterol and plasma glucose levels, indicating that functional lack of IL-6 may lead to insulin resistance and an atherogenic lipid profile (1, 5, 15). In accordance, IL-6 knockout mice develop late onset obesity and impaired glucose tolerance (26). Together, these studies add weight to the notion that IL-6 family cytokines are “anti-obesogenic.”Mechanisms of action.In isolated hepatocytes and in mice in vivo, IL-6 has a negative effect on hepatic insulin sensitivity. These findings are without clinical relevance as in vivo studies in humans clearly demonstrate that neither splanchnic glucose output measured by a-v balance across the hepatosplanchnic tissue nor isotopic tracer determined endogenous glucose production is increased by acute infusion of rhIL-6 (14, 17, 23). In vitro, IL-6 either enhances (4, 24) or does not enhance (13, 20) glucose transport in adipocytes. The fact that IL-6 infusion increases subcutaneous adipose tissue glucose uptake in humans (14) argues against IL-6 as an insulin resistance-inducing agent in adipocytes. In addition, several studies reported that IL-6 increases intramyocellular or whole body fatty acid oxidation, which is likely to decrease intramyocellular fatty acid accumulation, which can impair insulin signaling (reviewed in Ref. 4). With regard to myocytes, IL-6 enhances insulin-stimulated glucose transport (4) and glycogen synthesis (28). In vivo, experiments demonstrated that IL-6 increases basal and insulin-stimulated glucose uptake via an increased GLUT4 translocation (4).Recent evidence suggests a link between IL-6 and AMP-activated protein kinase (AMPK). AMPK activation stimulates fatty acid oxidation and increases glucose uptake (9). IL-6 was shown to enhance AMPK in both skeletal muscle and adipose tissue (10) and, more recently, the effects of IL-6 on enhanced glucose uptake in skeletal myotubes were abolished in cells infected with an AMPK-dominant negative construct (4). Studies have shown that IL-6 can enhance lipid oxidation in vitro (17), ex vivo (2), and in vivo (17, 25). AMPK phosphorylates ACC, resulting in inhibition of ACC activity, which in turn leads to a decrease in malonyl CoA content, relieving inhibition of CPT-1 and increasing fatty acid oxidation (9). We recently showed that the IL-6-mediated phosphorylation of ACC and subsequent palmitate oxidation is AMPK dependent (4). Our data, together with our recent findings regarding CNTF, which markedly enhances lipid oxidation via activation of AMPK (27), suggest that ligands that bind to the gp130 receptor complex can enhance glucose uptake and fat oxidation via activation of AMPK.IL-6 has been shown to activate SOCS proteins in liver, leading to hepatic insulin resistance (21). IL-6 increased SOCS3 expression in myotubes, but concomitantly increased glucose uptake in these cells (4). While IL-6 increased SOCS3 twofold in muscle, it was increased ∼25-fold in liver, suggesting that capacity for IL-6 to induce SOCS3 is much greater in hepatic tissue (29). The possibility exists that the negative effects of IL-6 on SOCS3 may be overridden by the positive effects on AMPK.IL-6 stimulates the production of anti-inflammatory cytokines (16) and suppresses TNF-α production in humans (22). Direct evidence for a role of TNF in insulin resistance in humans has been obtained (19) and it is likely that muscle-derived IL-6 offers protection against TNF-induced insulin resistance (16).If IL-6 is a good guy, why does it coexist with the bad guys?Subjects with risk genotypes for both TNF-α (AA; A shows increased TNF transcription) and IL-6 (CC; C shows decreased transcription) have the highest incidence of diabetes (12), favoring the theory that high levels of TNF-α and low production of IL-6 are determining factors in the metabolic syndrome. High circulating levels of IL-6 may or may not be found in patients with Type 2 diabetes, but in general IL-6 is not elevated in lean subjects with insulin resistance (3, 18). Given the different biological profiles of TNF-α and IL-6 and given that TNF-α can trigger IL-6 release, one theory holds that it is adipose tissue-derived TNF-α that is actually the “driver” behind the metabolic syndrome and that increased systemic levels of IL-6 reflect locally produced TNF-α (16). Although IL-6 increases and TNF-α decreases insulin-stimulated glucose uptake in adipocytes, the addition of TNF-α to IL-6 totally abolishes the enhanced insulin action, highlighting the notion that it is TNF, not IL-6, that is the “bad guy” (Hage M et al., unpublished observations).In summary, acute IL-6 administration to humans increases insulin-stimulated glucose disposal and fatty acid oxidation in vivo and IL-6 has strong anti-inflammatory effects. Activation of AMPK by IL-6 appears to play an important role in modulating some of these metabolic effects.GRANTSSupport was obtained from the Danish Medical Research Foundation, and the Commission of the European Communities (Contract No. LSHM-CT-2004–005272 EXGENESIS). Studies conducted by M. A. Febbraio were supported by grants from the National Health and Medical Research Council (NHMRC Project Grant Nos. 251558, 342115, 392206). M. A. Febbraio is a Senior Research Fellow of the NHMRC.We thank the Centre of Inflammation and Metabolism (supported by Danish National Research Foundation Grant DG 02–512-555) and the Copenhagen Muscle Research Centre (supported by grants from the University of Copenhagen, the Faculties of Science and of Health Sciences at this university, and the Copenhagen Hospital Corporation).REFERENCES1 Atlizumab: anti-IL6 receptor antibody-Chugai, anti-interleukin-6 receptor antibody-Chugai, MRA-Chugai. BioDrugs 17: 369–372, 2003.Crossref | PubMed | ISI | Google Scholar2 Bruce CR, Dyck DJ. Cytokine regulation of skeletal muscle fatty acid metabolism: effect of interleukin-6 and tumor necrosis factor-alpha. Am J Physiol Endocrinol Metab 287: E616–E621, 2004.Link | ISI | Google Scholar3 Carey AL, Bruce CR, Sacchetti M, Anderson MJ, Olson D, Saltin B, Hawley JA, Febbraio MA. Interleukin-6 and tumor necrosis factor-alpha are not increased in patients with type 2 diabetes: evidence that plasma IL-6 is related to fat mass and not insulin responsiveness. Diabetologia 47: 1029–1037, 2004.Crossref | PubMed | ISI | Google Scholar4 Carey AL, Steinberg GR, Macaulay SL, Thomas WG, Holmes AG, Ramm G, Prelovsek O, Hohnen-Behrens C, Watt MJ, James DE, Kemp BE, Pedersen BK, Febbraio MA. IL-6 increases insulin stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMPK. Diabetes 55: 2688–2697, 2006.Crossref | PubMed | ISI | Google Scholar5 Choy EH, Isenberg DA, Garrood T, Farrow S, Ioannou Y, Bird H, Cheung N, Williams B, Hazleman B, Price R, Yoshizaki K, Nishimoto N, Kishimoto T, Panayi GS. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 46: 3143–3150, 2002.Crossref | PubMed | Google Scholar6 Ettinger MP, Littlejohn TW, Schwartz SL, Weiss SR, McIlwain HH, Heymsfield SB, Bray GA, Roberts WG, Heyman ER, Stambler N, Heshka S, Vicary C, Guler HP. Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults: a randomized, dose-ranging study. JAMA 289: 1826–1832, 2003.Crossref | PubMed | ISI | Google Scholar7 Febbraio MA, Hiscock N, Sacchetti M, Fischer CP, Pedersen BK. Interleukin-6 is a novel factor mediating glucose homeostasis during skeletal muscle contraction. Diabetes 53: 1643–1648, 2004.Crossref | PubMed | ISI | Google Scholar8 Febbraio MA, Pedersen BK. Muscle-derived interleukin-6: mechanisms for activation and possible biological roles. FASEB J 16: 1335–1347, 2002.Crossref | PubMed | ISI | Google Scholar9 Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 1: 15–25, 2005.Crossref | PubMed | ISI | Google Scholar10 Kelly M, Keller C, Avilucea PR, Keller P, Luo Z, Xiang X, Giralt M, Hidalgo J, Saha AK, Pedersen BK. AMPK activity is diminished in tissues of the IL-6 knockout mice: the effect of exercise. Biochem Biophys Res Commun 320: 449–454, 2004.Crossref | PubMed | ISI | Google Scholar11 Kim HJ, Higashimori T, Park SY, Choi H, Dong J, Kim YJ, Noh HL, Cho YR, Cline G, Kim YB, Kim JK. Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes 53: 1060–1067, 2004.Crossref | PubMed | ISI | Google Scholar12 Kubaszek A, Pihlajamaki J, Komarovski V, Lindi V, Lindstrom J, Eriksson J, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Tuomilehto J, Uusitupa M, Laakso M. Promoter polymorphisms of the TNF-alpha (G-308A) and IL-6 (C-174G) genes predict the conversion from impaired glucose tolerance to type 2 diabetes: the Finnish Diabetes Prevention Study. Diabetes 52: 1872–1876, 2003.Crossref | PubMed | ISI | Google Scholar13 Lagathu C, Bastard JP, Auclair M, Maachi M, Capeau J, Caron M. Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone. Biochem Biophys Res Commun 311: 372–379, 2003.Crossref | PubMed | ISI | Google Scholar14 Lyngso D, Simonsen L, Bulow J. Interleukin-6 production in human subcutaneous abdominal adipose tissue: the effect of exercise. J Physiol 543: 373–378, 2002.Crossref | PubMed | ISI | Google Scholar15 Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Hashimoto J, Azuma J, Kishimoto T. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 50: 1761–1769, 2004.Crossref | PubMed | Google Scholar16 Petersen AM, Pedersen BK. The anti-inflammatory effect of exercise. J Appl Physiol 98: 1154–1162, 2005.Link | ISI | Google Scholar17 Petersen EW, Carey AL, Sacchetti M, Steinberg GR, Macaulay SL, Febbraio MA, and Pedersen BK. Acute IL-6 treatment increases fatty acid turnover in elderly humans in vivo and in tissue culture in vitro: evidence that IL-6 acts independently of lipolytic hormones. Am J Physiol Endocrinol Metab 288: E155–E162, 2005.Link | ISI | Google Scholar18 Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 350: 664–671, 2004.Crossref | PubMed | ISI | Google Scholar19 Plomgaard P, Bouzakri K, Krogh-Madsen R, Zierath JR, Pedersen BK. TNF-alpha induces skeletal muscle insulin resistance in healthy human subjects via inhibition of AS160 phosphorylation. Diabetes 54: 2939–2945, 2005.Crossref | PubMed | ISI | Google Scholar20 Rotter V, Nagaev I, Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3–L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem 278: 45777–45784, 2003.Crossref | PubMed | ISI | Google Scholar21 Senn JJ, Klover PJ, Nowak IA, Zimmers TA, Koniaris LG, Furlanetto RW, Mooney RA. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem 278: 13740–13746, 2003.Crossref | PubMed | ISI | Google Scholar22 Starkie R, Ostrowski SR, Jauffred S, Febbraio M, Pedersen BK. Exercise and IL-6 infusion inhibit endotoxin-induced TNF-alpha production in humans. FASEB J 17: 884–886, 2003.Crossref | PubMed | ISI | Google Scholar23 Steensberg A, Fischer CP, Sacchetti M, Keller C, Osada T, Schjerling P, van Hall G, Febbraio MA, Pedersen BK. Acute interleukin-6 administration does not impair muscle glucose uptake or whole body glucose disposal in healthy humans. J Physiol 548: 631–638, 2003.Crossref | PubMed | ISI | Google Scholar24 Stouthard JM, Oude Elferink RP, Sauerwein HP. Interleukin-6 enhances glucose transport in 3T3–L1 adipocytes. Biochem Biophys Res Commun 220: 241–245, 1996.Crossref | PubMed | ISI | Google Scholar25 Van Hall G, Steensberg A, Sacchetti M, Fischer C, Keller C, Schjerling P, Hiscock N, Moller K, Saltin B, Febbraio MA, Pedersen BK. Interleukin-6 stimulates lipolysis and fat oxidation in humans. J Clin Endocrinol Metab 88: 3005–3010, 2003.Crossref | PubMed | ISI | Google Scholar26 Wallenius V, Wallenius K, Ahren B, Rudling M, Carlsten H, Dickson SL, Ohlsson C, Jansson JO. Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 8: 75–79, 2002.Crossref | PubMed | ISI | Google Scholar27 Watt MJ, Dzamko N, Thomas WG, Rose-John S, Ernst M, Carling D, Kemp BE, Febbraio MA, Steinberg GR. CNTF reverses obesity-induced insulin resistance by activating skeletal muscle AMPK. Nat Med 12: 541–548, 2006.Crossref | PubMed | ISI | Google Scholar28 Weigert C, Hennige AM, Brodbeck K, Haring HU, Schleicher ED. Interleukin-6 (IL-6) acts as insulin sensitizer on glycogen synthesis in human skeletal muscle cells by phosphorylation of Ser-473 of Akt. Am J Physiol Endocrinol Metab 289: E251–E257, 2005.Link | ISI | Google Scholar29 Weigert C, Hennige AM, Lehmann R, Brodbeck K, Baumgartner F, Schauble M, Haring HU, Schleicher ED. Direct cross-talk of interleukin-6 and insulin signal transduction via insulin receptor substrate-1 in skeletal muscle cells. J Biol Chem 281: 7060–7067, 2006.Crossref | PubMed | ISI | Google Scholar30 Wojtaszewski JF, Jorgensen SB, Frosig C, Macdonald C, Birk JB, Richter EA. Insulin signalling: effects of prior exercise. Acta Physiol Scand 178: 321–328, 2003.Crossref | PubMed | Google ScholarjapJ Appl PhysiolJournal of Applied PhysiologyJ Appl Physiol8750-75871522-1601American Physiological SocietyjapJ Appl PhysiolJournal of Applied PhysiologyJ Appl Physiol8750-75871522-1601American Physiological SocietyjapJ Appl PhysiolJournal of Applied PhysiologyJ Appl Physiol8750-75871522-1601American Physiological SocietyCOUNTERPOINT: INTERLEUKIN-6 DOES NOT HAVE A BENEFICIAL ROLE IN INSULIN SENSITIVITY AND GLUCOSE HOMEOSTASISRobert A. MooneyDepartment of Pathology and Laboratory Medicine University of Rochester Medical Center Rochester, New YorkFebruary2007REBUTTAL FROM DRS. PEDERSEN AND FEBBRAIOFebruary2007REBUTTAL FROM DR. MOONEYFebruary2007Interleukin (IL)-6 is a pleiotropic cytokine with involvement in such diverse physiological and pathological functions as innate immunity and acute phase response, hematopoiesis, liver regeneration, and repair (1, 26). Evidence also supports a role for IL-6 in glucose metabolism and insulin action, but the nature of this role is controversial. As discussed by Dr. Pedersen and Dr. Febbraio, my Point:Counterpoint colleagues whose research has made major contributions to this field, IL-6 can display beneficial effects in regulating glucose metabolism, particularly in skeletal muscle (8). The important question as I see it, however, is whether IL-6, in pathological conditions, contributes to glucose dysregulation. Although IL-6 may have a benign or beneficial role under certain experimental conditions, I will argue that in its relationship to obesity and insulin resistance, which affects as many as one-third of adults in the United States, the contribution of IL-6 is decidedly detrimental, particularly in the liver.Recent evidence indicates that obesity, with its associated insulin resistance and Type 2 diabetes, is a chronic inflammatory state (29). Considerable effort is directed at determining the contribution of the cytokines, adipokines, and related factors to the altered glucose homeostasis and insulin resistance of this inflammatory state. Circulating IL-6 levels are two- to fourfold higher in obese, Type 2 diabetics than in nonobese controls (7, 17, 18). Kern et. al (12) reported that plasma IL-6 levels correlate better than TNF-α with obesity and insulin resistance. Similarly, Bastard et al. (3) reported that adipose tissue IL-6 levels but not TNF-α or leptin levels correlate with insulin resistance in obese subjects. IL-6 levels in serum and adipose tissue also decrease with weight loss (2). A recent study demonstrated that levels of CRP and IL-6 correlate with both insulin resistance and obesity and predict the development of Type 2 diabetes (19). Adipose tissue makes an important contribution to circulating IL-6 levels (16), and the liver is a well- characterized target of IL-6. Omental fat is more strongly linked to insulin resistance than non-visceral fat depots (6) and secretes as much as two- to threefold more IL-6 than subcutaneous fat (9). Importantly, venous drainage of omental fat uses the portal venous system, hence potentially having a preferential effect on the liver.Is IL-6 an active participant in the insulin resistance and altered carbohydrate metabolism of obesity or is this guilt by association? Both in vivo and in vitro evidence is available to address this question. Kanemaki et al. (11) and others (20) reported that IL-6 inhibits insulin-dependent glycogen synthesis and promotes glucose release from isolated primary hepatocytes. Our group has shown that IL-6 impairs insulin receptor signaling in HepG2 cells and primary hepatocytes and confirms that insulin-dependent glycogen synthesis is inhibited by IL-6 (23). Rotter et al. (21) reported that gene transcription of IRS-1, GLUT4, and PPAR-γ decreased in response to chronic IL-6 in 3T3L1 adipocytes. Insulin-dependent glucose transport and IRS-1 tyrosine phosphorylation were also suppressed.While in vitro investigations have shown direct inhibitory effects of IL-6 on insulin- responsive target cells, in vivo experiments also support such an effect of IL- 6. In rodents, IL-6 injections lead to increased plasma glucose and insulin levels after 90 min and a marked decrease in liver glycogen (25). Additionally, we reported that mice acutely exposed to IL-6 for 90 min have reduced insulin signal transduction in the liver (24). If the objective is to characterize the role of IL-6 in obesity, however, IL-6 levels should be maintained in a chronically elevated state to mimic obesity. To this end, we used implantable osmotic pumps that deliver IL-6 continuously to mice over 5–7 days. Under these conditions, IL-6 produced a hepatic insulin resistance as determined by impaired insulin receptor signal transduction. Interestingly, skeletal muscle response to insulin was unimpaired (15). Using a more acute IL-6 treatment, Kim et al. (13) infused IL-6 for 3 h during a hyperinsulinemic-euglycemic clamp study. Under these conditions, insulin resistance was observed in both the liver and skeletal muscle. Perhaps the latter reflects the higher dose used and the shorter time frame of the study.To directly address the role of IL-6 in glucose dysregulation of obesity, an IL-6 neutralizing antibody was used to deplete IL-6 in genetically obese Lepob mice (14). Prior to antibody treatment, elevated STAT3 phosphorylation and increased expression of acute phase proteins haptoglobin and fibrinogen were observed in liver and adipose tissue of the obese mice compared with lean controls, consistent with an obesity-associated elevation of endogenous IL-6. Neutralization of IL-6 returned these markers toward levels seen in lean mice. Importantly, insulin receptor signaling increased in the liver but not in adipose tissue in response to IL-6 depletion. Of relevance to our current discussion, depletion of IL-6 increased insulin sensitivity in the obese mice as reflected in a marked improvement in insulin-dependent suppression of endogenous glucose production (14). Cai et al. (4) reported a similar increase in hepatic insulin sensitivity following treatment of a transgenic mouse model of insulin resistance with IL-6 neutralizing antibody. They argue further that the liver can be an important source of IL-6, with steatosis being a potent stimulus for increased production.Is IL-6 a promoter of insulin sensitivity and glucose utilization as suggested in part by the expertly performed, acute, human studies by Drs. Pedersen, Febbraio, and colleagues, or is IL-6 the antagonist of insulin action as argued in the studies outlined here? What factors may account for the apparent contradictory effects of IL-6 on glucose homeostasis? Chronicity may be one factor. Most human investigations are by necessity limited to several hours. Obesity is a chronic condition, and the role of IL-6 in this condition may require chronic elevations. Chronic, but not acute, exposure to IL-6 causes inhibitory changes in insulin action in 3T3L1 adipocytes (21). Evidence from the liver regeneration field suggests that short-term (1–2 days) IL-6 exposure yields a protective effect, whereas long term (5–7 days) IL-6 exposure is injurious (10). Differences in response to IL-6 between the insulin responsive tissues are also a factor. While skeletal muscle appears to be the major target for the reported beneficial effects of IL-6, Weigert et al. (28) recently confirmed that, in the liver of mice, IL-6 activates two inhibitory mechanisms that are implicated in insulin resistance, marked induction of SOCS-3 and phosphorylation of IRS-1 on serine-307. Interestingly, IL-6 had no appreciable effect on these inhibitory mechanisms in skeletal muscle. Carey et al. (5) recently confirmed the small effect of IL-6 on SOCS-3 expression in muscle. This tissue-specific difference in induction of SOCS-3 may be quite relevant to this current discussion because we and others have linked SOCS-3 to inhibition of insulin receptor signal transduction in the liver (22, 24, 27). Finally, physiological context may play an important role in determining the response to an inflammatory cytokine such as IL-6. In 3T3L1 adipocytes, IL-6 alone had no acute effect and IL-1α had only a small inhibitory effect on insulin receptor signal transduction (28). Together, however, these two inflammatory cytokines very potently inhibited insulin receptor signaling. Thus, although considerable evidence supports a role for IL-6 in promoting insulin resistance and glucose dysregulation, optimum characterization of this role may require consideration of the synergy between IL-6 and other elements of the proinflammatory milieu.GRANTSThe author recognizes support from the National Institute of Diabetes and Digestive and Kidney Diseases (Grants DK-38138 and DK-60732) and the American Diabetes Association (7–04-RA-78). We thank Dr. Mooney for presenting his argument in a concise and scholarly fashion and acknowledge the contribution that his work has made to the field (6). We do not question the validity of the work that indicates that IL-6 may induce insulin resistance in some experimental models, but we feel that two critical issues have been neglected by Dr. Mooney. First, Dr. Mooney highlights that IL-6 is “associated” with insulin resistance in humans. However, association does not equate to causality. Dr. Mooney cites studies (1, 3) that show that IL-6 is associated with insulin resistance in humans, but we would also like to point out that, in our hands, IL-6 is strongly associated with obesity but not insulin resistance using the “gold standard” of measuring insulin sensitivity, the hyperinsulinemic euglycemic clamp (2). This suggests that IL-6 may be a consequence rather than a cause of insulin resistance and it is indeed dangerous to confuse the two. Second, notwithstanding the important issue of “chronicity,” all of the work that demonstrates a negative effect of chronic IL-6 in vivo, including the elegant work by Dr. Mooney, who has implanted mini osmotic pumps (5) or used IL-6 antibodies (4), has been performed in rodents. In humans, the effect seems opposite. As cited by us in our original Point article (8), blocking IL-6 in patients with rheumatoid arthritis causes hyperglycemia. Moreover, when a neutralizing anti-IL-6 receptor antibody is given to patients with multicentric Castleman disease for up to 60 wk, patients increase their body weight by 10% and become markedly hypertriglyceridemic (7), in perfect concordance with the work of Jansson and coworkers (10), who have examined the metabolic status of the IL-6 knockout mouse. These critical observations in humans (7) argue against the notion that IL-6 antibody treatment would be a favorable outcome for metabolic disease. Finally, as discussed in our original Point article (8), TNF-α and not IL-6 may indeed be the “sheep in wolf's clothing.” In a recent study (9), plasma-IL-6 concentrations were markedly lowered by anti-TNF-α therapy. This finding that plasma TNF-α was not elevated despite high levels of IL-6 and that plasma-IL-6 levels decreased in response to anti-TNF-α therapy supports the notion that TNF-α may stimulate IL-6 production and consequently IL-1ra and CRP. In line with this, chronically elevated levels of IL-6 are likely to reflect local ongoing TNF-α production, the real cause of cytokine-induced insulin resistance in humans.As anticipated, Drs. Pedersen and Febbraio do not view IL-6 as a bad guy in insulin action. Let's examine their argument. Acute IL-6 infusions in healthy adults have little or no effect on hepatic glucose metabolism while promoting utilization in skeletal muscle. The critical limitation of these infusion studies, however, is that they do not replicate the chronic elevation of IL-6 in obesity-associated insulin resistance. To date, no human studies adequately address chronic effects of IL-6 on insulin action. A polymorphism in the human IL-6 gene promoter at −174 may chronically affect circulating IL-6 and alter risk of insulin resistance and diabetes, but conclusions are conflicting. My colleagues cite one study (8) to support their arguments, but the report actually concludes that the C-174C genotype alone is not associated with diabetic risk. In another recent study, the G-174G genotype was associated with increased plasma IL-6 and reduced insulin sensitivity (2). My colleagues also cite human studies with IL-6 receptor blocking antibodies (1, 4, 9), but the articles actually make no mention of glucose levels. Unfortunately, no clinical studies with these antibodies have analyzed glucose metabolism.Without definitive human studies, an understanding of the effects of chronic IL-6" @default.
• W2012054395 created "2016-06-24" @default.
• W2012054395 creator A5013388710 @default.
• W2012054395 creator A5074362044 @default.
• W2012054395 date "2007-02-01" @default.
• W2012054395 modified "2023-10-18" @default.
• W2012054395 title "Interleukin-6 does/does not have a beneficial role in insulin sensitivity and glucose homeostasis" @default.
• W2012054395 cites W1534360145 @default.
• W2012054395 cites W1777081626 @default.
• W2012054395 cites W1970205234 @default.
• W2012054395 cites W1973416470 @default.
• W2012054395 cites W1989705016 @default.
• W2012054395 cites W1992527366 @default.
• W2012054395 cites W2000724007 @default.
• W2012054395 cites W2000846863 @default.
• W2012054395 cites W2006332285 @default.
• W2012054395 cites W2015757082 @default.
• W2012054395 cites W2018135697 @default.
• W2012054395 cites W2022713850 @default.
• W2012054395 cites W2024144587 @default.
• W2012054395 cites W2027670788 @default.
• W2012054395 cites W2033124959 @default.
• W2012054395 cites W2040901874 @default.
• W2012054395 cites W2043967275 @default.
• W2012054395 cites W2046419063 @default.
• W2012054395 cites W2048488935 @default.
• W2012054395 cites W2059652342 @default.
• W2012054395 cites W2061613314 @default.
• W2012054395 cites W2064119981 @default.
• W2012054395 cites W2067813522 @default.
• W2012054395 cites W2069711307 @default.
• W2012054395 cites W2074494152 @default.
• W2012054395 cites W2078325369 @default.
• W2012054395 cites W2080999576 @default.
• W2012054395 cites W2084325067 @default.
• W2012054395 cites W2084483597 @default.
• W2012054395 cites W2085073265 @default.
• W2012054395 cites W2090165963 @default.
• W2012054395 cites W2097447032 @default.
• W2012054395 cites W2098882931 @default.
• W2012054395 cites W2109384991 @default.
• W2012054395 cites W2112857693 @default.
• W2012054395 cites W2114280375 @default.
• W2012054395 cites W2116662308 @default.
• W2012054395 cites W2126393987 @default.
• W2012054395 cites W2127647469 @default.
• W2012054395 cites W2128600629 @default.
• W2012054395 cites W2130078845 @default.
• W2012054395 cites W2139406934 @default.
• W2012054395 cites W2145229644 @default.
• W2012054395 cites W2148378054 @default.
• W2012054395 cites W2153599456 @default.
• W2012054395 cites W2155824086 @default.
• W2012054395 cites W2156090925 @default.
• W2012054395 cites W2162129832 @default.
• W2012054395 cites W2171799063 @default.
• W2012054395 cites W2175474731 @default.
• W2012054395 cites W4241510428 @default.
• W2012054395 cites W4252306180 @default.
• W2012054395 cites W4254766067 @default.
• W2012054395 doi "https://doi.org/10.1152/japplphysiol.01208.2006" @default.
• W2012054395 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17068210" @default.
• W2012054395 hasPublicationYear "2007" @default.
• W2012054395 type Work @default.
• W2012054395 sameAs 2012054395 @default.
• W2012054395 citedByCount "153" @default.
• W2012054395 countsByYear W20120543952012 @default.
• W2012054395 countsByYear W20120543952013 @default.
• W2012054395 countsByYear W20120543952014 @default.
• W2012054395 countsByYear W20120543952015 @default.
• W2012054395 countsByYear W20120543952016 @default.
• W2012054395 countsByYear W20120543952017 @default.
• W2012054395 countsByYear W20120543952018 @default.
• W2012054395 countsByYear W20120543952019 @default.
• W2012054395 countsByYear W20120543952020 @default.
• W2012054395 countsByYear W20120543952021 @default.
• W2012054395 countsByYear W20120543952022 @default.
• W2012054395 countsByYear W20120543952023 @default.
• W2012054395 crossrefType "journal-article" @default.
• W2012054395 hasAuthorship W2012054395A5013388710 @default.
• W2012054395 hasAuthorship W2012054395A5074362044 @default.
• W2012054395 hasConcept C126322002 @default.
• W2012054395 hasConcept C134018914 @default.
• W2012054395 hasConcept C185592680 @default.
• W2012054395 hasConcept C2777391703 @default.
• W2012054395 hasConcept C2779306644 @default.
• W2012054395 hasConcept C3017594256 @default.
• W2012054395 hasConcept C3018667095 @default.
• W2012054395 hasConcept C63645605 @default.
• W2012054395 hasConcept C71924100 @default.
• W2012054395 hasConcept C86803240 @default.
• W2012054395 hasConceptScore W2012054395C126322002 @default.
• W2012054395 hasConceptScore W2012054395C134018914 @default.
• W2012054395 hasConceptScore W2012054395C185592680 @default.
• W2012054395 hasConceptScore W2012054395C2777391703 @default.
• W2012054395 hasConceptScore W2012054395C2779306644 @default.
• W2012054395 hasConceptScore W2012054395C3017594256 @default.
• W2012054395 hasConceptScore W2012054395C3018667095 @default.

• next